Filter zurücksetzen
Stichworte
Neuroblastom ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
    1. 7.1. Anästhesie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Geriatrie
    1. 7.5. Gynäkologie/Geburtshilfe
    1. 7.6. Innere Medizin
      1. Hämatologie
      1. Infektiologie
      1. Kardiologie/Angiologie
      1. Pneumologie
      1. Gastroenterologie
      1. Nephrologie
      1. Endokrinologie/Stoffwechsel
      1. Rheumatologie
    1. 7.7. Neurologie
    1. 7.8. Augenheilkunde
    1. 7.9. Palliativmedizin
    1. 7.10. Pathologie/Rechtsmedizin
    1. 7.11. Kinderheilkunde
    1. 7.12. Psychiatrie/Psychosomatik
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Allgemein-/Viszeralchirurgie
      1. Neurochirurgie
      1. Plastische Chirurgie
      1. Herz-/Thoraxchirurgie
      1. Unfallchirurgie/Orthopädie
      1. Gefäßchirurgie
    1. 7.15. Urologie
    1. 7.16. Zahnmedizin/MKG
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

21 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

dbGaP phs000868 Transcriptome Sequencing of Pediatric Neuroblastoma - Eligibility

- 16.03.24 - 5 Formulare, 1 Itemgruppe, 1 Datenelement, 1 Sprache
Itemgruppe: IG.elig
Principal Investigator: Javed Khan, National Institutes of Health, Bethesda, MD, USA MeSH: Neuroblastoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000868 Neuroblastoma is the most common extra-cranial solid tumor in children. It represents 8% to 10% of all childhood cancers. Stage 4 Neuroblastoma is characterized by its clinical heterogeneous outcome. The special category, stage 4S tumors (2-5% of all NB) are chemo-sensitive, and the patients show spontaneous regression. On the other hand, MYCN amplification (25-30% of all NB) is associated with poor outcome of neuroblastoma, thus we further categorize stage 4 neuroblastoma into MYCN non-amplified and MYCN amplified group. Here we use transcriptome sequencing to characterize the transcriptome in 29 stage 4 Neuroblastoma samples.

pht004587.v1.p1

1 Itemgruppe 2 Datenelemente

pht004588.v1.p1

1 Itemgruppe 3 Datenelemente

pht004589.v1.p1

1 Itemgruppe 2 Datenelemente

pht004590.v1.p1

1 Itemgruppe 7 Datenelemente

Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314 - Therapy and toxicity cycle 10-13

- 20.09.21 - 16 Formulare, 16 Itemgruppen, 68 Datenelemente, 1 Sprache
Itemgruppen: Therapy cycle 10-13, Therapy after cycle, Propranolol, Propranolol therapy deviation, Celecoxib, Celecoxib deviation, Cyclophosphamide, Cyclophosphamide deviation, Vinblastine, Vinblastine deviation, Toxicity overview, Toxicity, Hospitalization, Comments, Transfusion, Footer module
NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln

Therapy and toxicity cycle > 13

16 Itemgruppen 68 Datenelemente

Therapy and toxicity cycle 1-3

16 Itemgruppen 68 Datenelemente

Therapy and toxicity cycle 4-6

16 Itemgruppen 68 Datenelemente

Therapy and toxicity cycle 7-9

16 Itemgruppen 68 Datenelemente

Baseline

13 Itemgruppen 77 Datenelemente

Reference

12 Itemgruppen 111 Datenelemente

ANBL0321 MIBG Response NCT00053326

- 20.09.21 - 1 Formular, 5 Itemgruppen, 6 Datenelemente, 1 Sprache
Itemgruppen: Header, Period Number, Tumor Response, Comments, CCRR MODULE
ANBL0321 MIBG Response NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B968BED1-43CF-22DE-E034-0003BA12F5E7

ANBL0321: Death Worksheet NCT00053326

- 05.07.15 - 1 Formular, 3 Itemgruppen, 17 Datenelemente, 1 Sprache
Itemgruppen: Header, Death Assessment, CCRR MODULE
ANBL0321: Death Worksheet NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B9B55D16-FD2B-1EE8-E034-0003BA12F5E7

ANBL0321: On Study Worksheet NCT00053326

- 03.07.15 - 1 Formular, 4 Itemgruppen, 24 Datenelemente, 1 Sprache
Itemgruppen: Header, Miscellaneous Patient Information, Comments, CCRR MODULE
ANBL0321: On Study Worksheet NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B9543982-264A-44CD-E034-0003BA12F5E7

ANBL0321: Eligibility Worksheet NCT00053326

- 27.06.15 - 1 Formular, 5 Itemgruppen, 30 Datenelemente, 1 Sprache
Itemgruppen: Header, Eligibility Assessment, Performance status, Comments, CCRR MODULE
ANBL0321: Eligibility Worksheet NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C42A6818-CD59-6B25-E034-0003BA12F5E7

Baseline Abnormalities [ANBL0321] NCT00053326

- 21.06.15 - 1 Formular, 3 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Header, Baseline Abnormalities, CCRR MODULE
Baseline Abnormalities [ANBL0321] NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C3B3D263-6B48-4DA2-E034-0003BA12F5E7

Neuroblastoma (NCT00053326) - End of Course Worksheet (ANBL0321 NCT00053326)

- 19.03.15 - 1 Formular, 4 Itemgruppen, 46 Datenelemente, 1 Sprache
Itemgruppen: Header, Tumor therapy, Patient status, Adverse event
ANBL0321: End of Course Worksheet Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C42A83E1-AFEA-713E-E034-0003BA12F5E7

ANBL0321: Prior Therapy Worksheet NCT00053326

- 03.07.15 - 1 Formular, 7 Itemgruppen, 21 Datenelemente, 1 Sprache
Itemgruppen: Header, Cancer Prior Treatment, Type of Prior Therapy, Stem cell transplant, Comments, General Validations/Notes, CCRR MODULE
ANBL0321: Prior Therapy Worksheet NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B92CFA2B-A3FF-34F4-E034-0003BA12F5E7

ANBL0321: Relapse/Progression Worksheet NCT00053326

- 03.07.15 - 1 Formular, 3 Itemgruppen, 13 Datenelemente, 1 Sprache
Itemgruppen: Header, Relapse/Progression, CCRR MODULE
ANBL0321: Relapse/Progression Worksheet NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B968B3D2-B7BF-21FC-E034-0003BA12F5E7

ANBL0321: Secondary Malignancy Worksheet NCT00053326

- 21.06.15 - 1 Formular, 3 Itemgruppen, 13 Datenelemente, 1 Sprache
Itemgruppen: Header, Secondary Malignancy, CCRR MODULE
ANBL0321: Secondary Malignancy Worksheet NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B96858A4-76C7-1B0B-E034-0003BA12F5E7

ANBL0321: Bone Marrow Response NCT00053326

- 16.06.15 - 1 Formular, 3 Itemgruppen, 13 Datenelemente, 1 Sprache
Itemgruppen: Header, Bone Marrow Response, CCRR MODULE
ANBL0321: Bone Marrow Response NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B9B4AFEC-3E03-1FF8-E034-0003BA12F5E7

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video